Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct) a randomised, double-blind, placebo-controlled phase 3 trial /

Trøseid Marius, Arribas José R, Assoumou Lambert, Holten Aleksander Rygh, Poissy Julien, Terzić Vida, Mazzaferri Fulvia, Baño Jesús Rodríguez, Eustace Joe, Hites Maya, Joannidis Michael, Paiva José-Artur, Reuter Jean, Püntmann Isabel, Patrick-Brown Thale D J H, Westerheim Elin, Nezvalova-Henriksen Katerina, Beniguel Lydie, Dahl Tuva Børresdatter, Bouscambert Maude, Halanova Monika, Péterfi Zoltán, Tsiodras Sotirios, Rezek Michael, Briel Matthias, Ünal Serhat, Schlegel Martin, Ader Florence, Lacombe Karine, Amdal Cecilie Delphin, Kollaborációs szervezet: EU SolidAct study group, Hajdu Edit, et al
2023

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy) a phase 3, randomized, double-blind, placebo-controlled trial. /

Hites Maya, Massonnaud Clément R, Jamard Simon, Goehringer François, Danion François, Reignier Jean, de Castro Nathalie, Garot Denis, Lapique Eva Larranaga, Lacombe Karine, Tolsma Violaine, Faure Emmanuel, Malvy Denis, Staub Thérèse, Courjon Johan, Cazenave-Roblot France, Riise Anne Ma Dyrhol, Leturnier Paul, Martin-Blondel Guillaume, Roger Claire, Akinosoglou Karolina, Moing Vincent Le, Piroth Lionel, Sellier Pierre, Lescure Xavier, Trøseid Marius, Clevenbergh Philippe, Dalgard Olav, Gallien Sébastien, Gousseff Marie, Hajdú Edit, Kollaborációs szervezet: DisCoVeRy study group, et al
2024